[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639579":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":32,"responsibleParty":194,"collaborators":26,"id":196,"slug":26,"hasResults":197,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":197,"sex":203,"minAge":204,"maxAge":205,"enrollmentInfo":206,"targetDuration":26,"studyType":209,"phases":210,"briefSummary":212,"conditions":213,"keywords":26,"overallStatus":215,"whyStopped":26,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":220,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Anlotinib + Benmelstobart","EXPERIMENTAL","Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)； Benmelstobart 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle",[13],"Drug: Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy",{"label":15,"type":16,"description":17,"interventionNames":18},"Upfront partial nephrectomy (standard care)","ACTIVE_COMPARATOR","Patients receive upfront partial nephrectomy",[19],"Procedure: Partial nephrectomy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy","Patients receive neoadjuvant therapy with oral anlotinib hydrochloride capsules and intravenous benmelstobart injection, followed by partial nephrectomy for localized renal cell carcinoma.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"PROCEDURE","Partial nephrectomy","Patients receive upfront partial nephrectomy without neoadjuvant therapy, as the standard treatment for localized renal cell carcinoma.",[15],[33,48,59,70,81,92,103,114,125,138,149,160,172,183],{"facility":34,"status":26,"city":35,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Peking University Third Hospital","Beijing","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":26,"phoneExt":26,"email":26},"Shudong Zhang","CONTACT",{"facility":49,"status":26,"city":50,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Jilin Provincial Cancer Hospital","Changchun",{"type":39,"coordinates":52},[53,54],125.32278,43.88,{"lat":54,"lon":53},[57],{"name":58,"role":47,"phone":26,"phoneExt":26,"email":26},"Changdong Zhou",{"facility":60,"status":26,"city":61,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Hunan Provincial Cancer Hospital","Changsha",{"type":39,"coordinates":63},[64,65],112.97087,28.19874,{"lat":65,"lon":64},[68],{"name":69,"role":47,"phone":26,"phoneExt":26,"email":26},"Xie Yu",{"facility":71,"status":26,"city":72,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou",{"type":39,"coordinates":74},[75,76],120.16142,30.29365,{"lat":76,"lon":75},[79],{"name":80,"role":47,"phone":26,"phoneExt":26,"email":26},"Dan Xia",{"facility":82,"status":26,"city":83,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Yunnan Provincial Cancer Hospital","Kunming",{"type":39,"coordinates":85},[86,87],102.71833,25.03889,{"lat":87,"lon":86},[90],{"name":91,"role":47,"phone":26,"phoneExt":26,"email":26},"Yong Yang",{"facility":93,"status":26,"city":94,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Nanjing Drum Tower Hospital","Nanjing",{"type":39,"coordinates":96},[97,98],118.77778,32.06167,{"lat":98,"lon":97},[101],{"name":102,"role":47,"phone":26,"phoneExt":26,"email":26},"Hongqian Guo",{"facility":104,"status":26,"city":105,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"The First Affiliated Hospital of Guangxi Medical University","Nanning",{"type":39,"coordinates":107},[108,109],108.31667,22.81667,{"lat":109,"lon":108},[112],{"name":113,"role":47,"phone":26,"phoneExt":26,"email":26},"Jiwen Chen",{"facility":115,"status":26,"city":116,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"The Affiliated Hospital of Qingdao University","Qingdao",{"type":39,"coordinates":118},[119,120],120.38042,36.06488,{"lat":120,"lon":119},[123],{"name":124,"role":47,"phone":26,"phoneExt":26,"email":26},"Ke Wang",{"facility":126,"status":26,"city":127,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Huadong Hospital Affiliated to Fudan University","Shanghai",{"type":39,"coordinates":129},[130,131],121.45806,31.22222,{"lat":131,"lon":130},[134],{"name":135,"role":47,"phone":136,"phoneExt":26,"email":137},"Hailiang Zhang","+86135 2407 1783","zhanghl918@163.com",{"facility":139,"status":26,"city":140,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Liaoning Provincial Cancer Hospital","Shenyang",{"type":39,"coordinates":142},[143,144],123.43278,41.79222,{"lat":144,"lon":143},[147],{"name":148,"role":47,"phone":26,"phoneExt":26,"email":26},"Bing Hu",{"facility":150,"status":26,"city":151,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Shanxi Province Cancer Hospital","Taiyuan",{"type":39,"coordinates":153},[154,155],112.56028,37.86944,{"lat":155,"lon":154},[158],{"name":159,"role":47,"phone":26,"phoneExt":26,"email":26},"Xuebing Han",{"facility":5,"status":26,"city":161,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Tianjin",{"type":39,"coordinates":163},[164,165],117.17667,39.14222,{"lat":165,"lon":164},[168],{"name":169,"role":47,"phone":170,"phoneExt":26,"email":171},"Yao Xin, Ph.D.","+86-02223340123","yaoxin@tjmuch.com",{"facility":173,"status":26,"city":174,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan",{"type":39,"coordinates":176},[177,178],114.26667,30.58333,{"lat":178,"lon":177},[181],{"name":182,"role":47,"phone":26,"phoneExt":26,"email":26},"Xiaoping Zhang",{"facility":184,"status":26,"city":185,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou",{"type":39,"coordinates":187},[188,189],113.64861,34.75778,{"lat":189,"lon":188},[192],{"name":193,"role":47,"phone":26,"phoneExt":26,"email":26},"Xuepei Zhang",{"type":195,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100639579",false,"NCT07627464","Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy","A Multicenter, Randomized Controlled Phase II Study of Neoadjuvant Anlotinib Hydrochloride Capsules Combined With Benmelstobart Injection Versus Surgery Alone for Localized Renal Cell Carcinoma Planned for Partial Nephrectomy","ALTER-UC-011","Inclusion Criteria:\n\n1. Aged between 18 and 75 years, inclusive.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n3. Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy.\n4. Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n5. No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy.\n\nExclusion Criteria:\n\n1. Subjects with a solitary kidney tumor.\n2. Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2).\n3. Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau \\[VHL\\] disease).\n4. Subjects with a prior history of renal transplantation.","ALL","18 Years","75 Years",{"count":207,"type":208},144,"ESTIMATED","INTERVENTIONAL",[211],"PHASE2","Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy",[214],"Renal Cell Carcinoma (RCC)","NOT_YET_RECRUITING","2026-05-31",{"date":218,"type":219},"2026-06-04","ACTUAL",{"date":216,"type":208},{"date":222,"type":208},"2029-12-31",{"name":5,"class":6},14]